View presentation

CLINICAL AND ECONOMIC IMPACT OF THE INTRODUCTION OF THE VACCINE
AGAINST MENINGOCOCCAL MENINGITIS C IN CHILDREN AGED 0-4 YEARS IN
BRAZIL
Andrade TRM¹, Sansone D¹, Etto H¹, Decimoni TC¹, Araujo GTB¹, Fonseca M¹ ²
1Axia.Bio Life Sciences International, Miami, USA ²Federal University of São Paulo, São Paulo, Brazil
160
R$300.000.000,00
140
R$250.000.000,00
120
100
R$200.000.000,00
80
60
40
20
R$50.000.000,00
0
2009 2010 2011 2012 2013
Years
Figure 3. Costs related to the management
and sequelae of the meningococcal C
meningitis for the period of 2009 to 2013 in
Brazil.
R$2.000.000,00
Expenditure
R$1.600.000,00
R$1.200.000,00
R$800.000,00
R$400.000,00
Figure 1. Cases of meningococcal C
meningitis in Brazil from 2009 to 2013
Vaccination cost of eligible
population
Quantity of cases
Disease Management
Sequelae
Figure 4. Cost estimate to the public
treasury
of
three
doses
of
the
meningococcal C vaccine for children in
their first year
600
500
400
300
200
100
0
2009 2010 2011 2012 2013
Years
Years
CONCLUSIONS
REFERENCES
RESULTS
700
R$-
The introduction of the vaccine against
meningococcus type C in SUS (Unified Health
System - Sistema Único de Saúde) –The
Brazilian public health system – for infants in
their first year of life generated reduction of the
incidence, mortality and sequelae due to
meningococcal C meningitis , decreasing, over
the years, the cost due to the disease and to its
sequelae, although adding the cost with
vaccination.
R$0,00
800
R$150.000.000,00
R$100.000.000,00
METHODS
The analysis was developed for the period
from 2009 to 2013. The actual number of
cases of the disease recorded in the
Diseases Notification Information System
and the deaths due to meningococcus C
meningitis obtained from the Mortality
Information System were considered. Also,
estimates of long-term sequelae (amputation,
skin scarring, renal failure, neurological
sequelae and deafness) and of the costs due
to sequelae, disease and vaccination were
considered.
Figure 5. Estimate of the value spent by
the government in the evaluated years.
Expenditure
The meningococcus (Neisseria meningitidis)
is currently the leading cause of bacterial
meningitis in Brazil. An invasive Neisseria
meningitidis infection has a wide spectrum of
clinical disease and meningitis is the most
frequently
observed
clinical
form.
Meningococcal disease develops rapidly, is
severe and has a high lethality. It also
presents high morbidity, particularly among
infants and young children, such as
amputations, renal dysfunction, skin scarring
and deafness. In addition, it has an epidemic
nature which makes the possibility of
preventing this infection through vaccination
of utmost importance. In 2010, the Ministry
of Health, through the National Immunization
Program, incorporated in the Basic Child
Vaccination Schedule, the meningococcal C
Conjugate vaccine. The objective of this
study is to evaluate the clinical and
economic impact of the incorporation of the
monovalent conjugate vaccine against
meningitis C caused by the Neisseria
meningitides bacterium in children aged 0-4
years in the Brazilian public health system.
Number of deaths due to meningitis
INTRODUCTION
Figure 2. Number of deaths due to
meningococcal C meningitis for the period
of 2009 to 2013 in Brazil
R$300.000.000,00
R$250.000.000,00
R$200.000.000,00
R$150.000.000,00
R$100.000.000,00
R$50.000.000,00
R$-
Years
1- Ministério do Planejamento, Orçamento e Gestão. Instituto
Brasileiro de Geografia e Estatística - IBGE. Contagem
Populacional. Available from:.[Accessed in March 2014].
2- Stella-Silva N, Oliveira SA, Marzochi KB. Rev Soc Bras Med
Trop 2007;40:304–10.
3- Ministério da Saúde. Sistema de Informação sobre Agravos de
Notificação
(SINAN).
Available
from:
http://dtr2004.saude.gov.br/sinanweb/index.php [Accessed March
2014].[database on the Internet].
4- Ministério da Saúde. Indicadores e Dados Básicos - Brasil 2012.
IDB
Brasil-2012.
Available
from:
http://tabnet.datasus.gov.br/cgi/idb2012/matriz.htm.[Accessed in
March 2014].
5- Ministério da Saúde. DATASUS. Sistema de Informação
Hospitalar
(SIH/DATASUS).
Available
from:http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sih/cnv/sxuf.def
. [Acessed march 2014].[database on the Internet].
6- Ministério da Saúde. DATASUS. Sistema de Informação
Ambulatorial
(SIA/DATASUS).
Available
from:
http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sia/cnv/qbuf.def.
[Acessed march 2014]. [database on the Internet].
7- Ministério da Saúde. SIGTAP - Sistema de Gerenciamento da
Tabela de Procedimentos, Medicamentos e OPM do SUS.
Available
from:
http://sigtap.datasus.gov.br/tabelaunificada/app/sec/procedimento/publicados/consultar.
[Acessed
march 2014].[database on the Internet].
8- AACD, Disabled Child Assistance Association (Associação de
Assistência à Criança Deficiente). 2006.
9- Sesso Rde C, Lopes AA, Thomé FS, Lugon JR, Watanabe
Y, Santos DR. [Chronic dialysis in Brazil: report of the Brazilian
dialysis census, 2011]. J Bras Nefrol. 2012 Jul-Sep;34(3):272-7.
10- Fundação Ezequiel Dias. Vacina contra meningite. Available
in:
http://funed.mg.gov.br/noticias/vacina-contra-meningite.
Accessed in April 2014.
11- Ministério da Saúde. SI-PNI - Sistema de Informação do
Programa
Nacional
de
Imunizações.
Available
from:
http://pni.datasus.gov.br/. Accessed in March 2014].